STOCK TITAN

Regulus Therapeu - RGLS STOCK NEWS

Welcome to our dedicated page for Regulus Therapeu news (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeu stock.

Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical innovator focused on developing microRNA-targeted therapies through advanced oligonucleotide technology. This page serves as the definitive source for official company announcements, research milestones, and regulatory developments.

Investors and researchers will find timely updates on clinical trial progress, including the Phase 1b study of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). Our curated news collection provides essential insights into therapeutic advancements, partnership agreements, and strategic initiatives shaping the company's trajectory.

The repository features rigorously verified information across key categories: clinical program updates, financial disclosures, intellectual property developments, and scientific publications. Each entry maintains factual accuracy while highlighting implications for Regulus' position in the precision medicine landscape.

Bookmark this page for direct access to primary source materials from Regulus Therapeutics. Regularly updated content ensures stakeholders maintain current understanding of the company's progress in addressing complex diseases through RNA-targeted therapeutics.

Rhea-AI Summary

Regulus Therapeutics Inc (Nasdaq: RGLS) announced that the FDA has accepted its IND application for RGLS8429, a treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). This approval allows the company to move forward with its planned Phase 1 clinical study in healthy volunteers, slated for the second quarter of 2022. The study aims to evaluate the safety and pharmacokinetics of RGLS8429, with subsequent Phase 1b trials to assess its efficacy in ADPKD patients. Regulus anticipates initiating patient dosing in the latter half of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
58.82%
Tags
none
-
Rhea-AI Summary

Regulus Therapeutics Inc. (Nasdaq: RGLS) will report its first quarter 2022 financial results on May 12, 2022, after market close. A live conference call and webcast will be held at 5:00 PM ET the same day to discuss these results and offer a corporate update. Investors can access the call by dialing (866) 652-5200 domestically. Regulus focuses on developing innovative medicines targeting microRNAs and holds a strong intellectual property portfolio in this field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
-
Rhea-AI Summary

Regulus Therapeutics (RGLS) has announced the initiation of preclinical studies targeting miR-155 for the treatment of Amyotrophic Lateral Sclerosis (ALS), in collaboration with Brigham and Women's Hospital. This collaboration, established in September 2021, aims to explore the efficacy of miR-155 inhibitors in both in vitro and in vivo models of ALS. Preliminary data is anticipated in the second half of 2022. Research indicates that blocking miR-155 can positively impact ALS progression, highlighting the potential of these compounds as therapeutic candidates for this severe neurodegenerative disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Regulus Therapeutics Inc. (Nasdaq: RGLS) reported financial results for the fourth quarter and full year ending December 31, 2021. The company had a net loss of $7.1 million for Q4 and $27.8 million for the year, compared to $1.3 million and $15.7 million in 2020, respectively. Cash and cash equivalents stood at $60.4 million at year-end. Significant progress was made in their ADPKD program with RGLS8429, having completed a Pre-IND meeting with the FDA. The company closed a $34.6 million private placement in November 2021 to support clinical development activities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary

Regulus Therapeutics Inc. (Nasdaq: RGLS) announced a conference call to discuss its fourth quarter and year-end 2021 financial results, scheduled for March 10, 2022, at 5:00 PM ET. Subsequently, management will provide updates on its developments, including its RGLS8429 program. Regulus emphasizes its focus on innovative medicines targeting microRNAs while cautioning that forward-looking statements about clinical studies and potential impacts from COVID-19 may vary from actual results. Access details for the live call and a replay option post-event are provided.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Regulus Therapeutics Inc. (Nasdaq: RGLS) has completed enrollment in the Phase 2 HERA clinical trial for lademirsen, targeting Alport Syndrome, a genetic nephrology disease with no current treatments. Under a partnership with Sanofi, the study will evaluate safety and efficacy in adult patients. Final results are anticipated in the first half of 2023. Regulus is eligible for up to $35 million in milestone payments from Sanofi, with $10 million already received for prior achievements. This trial represents a significant step in developing treatments for kidney diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Regulus Therapeutics Inc (Nasdaq: RGLS) announced that its CEO, Jay Hagan, will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 3:00 p.m. ET. A live webcast of the event will be available on the investor relations section of the Company's website, with a replay accessible for 90 days post-event. Regulus focuses on developing innovative medicines targeting microRNAs and possesses a robust intellectual property portfolio in this field, headquartered in San Diego, CA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Regulus Therapeutics (Nasdaq: RGLS) announced the successful completion of a pre-investigational new drug (Pre-IND) meeting with the FDA regarding its compound RGLS8429, aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). The FDA approved the trial design and dosing plan, allowing Regulus to submit an IND application in Q2 2022 for a Phase 1 clinical trial. The study will assess the drug's safety, tolerability, and dose response in healthy volunteers and ADPKD patients, with expected data releases in 2022 and 2023. The company also secured $34.6 million in funding to support this clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary

Regulus Therapeutics Inc. (Nasdaq: RGLS) announced that Jay Hagan, President and CEO, will present at the H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022. An on-demand webcast will be available on January 10, 2022, at 7:00 a.m. ET. The presentation will focus on the company's innovative medicines targeting microRNAs. The webcast will be accessible via the investor relations section of their website, with a replay archived for 30 days.

Regulus, headquartered in San Diego, CA, has developed a robust pipeline and holds significant intellectual property in the microRNA domain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
conferences
Rhea-AI Summary

Regulus Therapeutics Inc. (Nasdaq: RGLS) announced the appointment of Mohammad Ahmadian, Ph.D., as Vice President of Chemistry and Pharmaceutical Development. Dr. Ahmadian brings over 20 years of experience in drug discovery, particularly in oligonucleotides, and will oversee the R&D of drug candidates, including RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD). He was previously at Kinovate Life Sciences, focusing on operations and quality control. Alongside his role, he received an option to purchase 200,000 shares at $0.36 each, vesting over four years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
management
Regulus Therapeu

Nasdaq:RGLS

RGLS Rankings

RGLS Stock Data

136.46M
64.80M
2.18%
82.48%
3.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO